Infectious Diseases

MMR coverage remained below herd immunity 20 months after an Ohio outbreak, with minimal gains and persistent disparities in children.

A nationwide analysis of nearly 300,000 infants found that maternal RSV vaccination reduced severe infant hospitalizations by over 80%.

An analysis found nirsevimab was associated with substantial reductions in RSV-related hospitalizations among preterm infants and those with congenital heart disease.

Combined use of nirsevimab and maternal RSV vaccination was associated with a 43% reduction in RSV-related hospitalizations and ED visits among infants.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

New data reveal that implementing rapid diagnostic testing for RSV reduces the rate of unnecessary antibiotic prescriptions for viral respiratory infections.

Clesrovimab has been shown to maintain RSV-protection in infants across 2 RSV seasons, while also having positive safety data.

Clinical trial data demonstrate that clesrovimab maintains a safety profile comparable to palivizumab while providing significant protection against RSV-related infections.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Trial data indicate that clesrovimab has a safety profile comparable to palivizumab and maintained protection against RSV-related infections.

A study found that a nirsevimab immunization program reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second.

Whole-genome sequencing revealed extensive NICU transmission of MSSA and MRSA strains linked to invasive infection.

The AAP released its 2026 childhood immunization schedule, maintaining evidence-based vaccine recommendations and expanding guidance across routine, catch-up, and risk-based care.

FDA-cleared Flowflex Plus 4-in-1 home test detects RSV, influenza A/B, and COVID-19 in adults and children as young as 6 months.

Influenza antiviral use among hospitalized US children declined during the late COVID-19 pandemic despite guideline recommendations.

Long-acting injectable HIV treatment given every 2 months was safe, well tolerated, and strongly preferred by adolescents in a recent study.

Adolescents with HIV reported strong preference, viral suppression, and favorable safety outcomes after switching to long-acting injectable treatment.

Maternal influenza and TDaP vaccination during pregnancy was associated with fewer influenza- and pertussis-related hospital and ED visits in infants younger than 6 months.

ACIP recommends use of GSK’s pentavalent MenACWY-CRM/MenB-4C vaccine when MenACWY and MenB are indicated at the same visit.

Reactions from the pediatric health care community poured in following swift changes to the US childhood vaccine schedule by the CDC.

Effective immediately, the updated US childhood vaccine schedule will reduce the number of recommended vaccines for all children to 11 diseases, down from 18.

Those with regular access to care who did not receive, or were late on 2- and 4-month recommended vaccines, were more likely to not have any MMR vaccine by 2 years of age.

In this recap article, take a look back at some of our top stories in the infectious diseases space in 2025.

“We started out 2025 with an environment that was rife with myths and disinformation," said Robert H. Hopkins, Jr., MD, in this year-end recap of 2025 and the pediatric vaccine landscape.

Climate lag time poses urgent health risks for children, necessitating proactive pediatric care and policy changes to address future climate-related challenges.